Last update: 22.07.2024 17:09 (GMT+3)

TFA: ADDITIONAL INFORMATION

01.08.2003, Tallinna Farmaatsiatehas, TLN

Tallinna Farmaatsiatehas NEWS RELEASE 08/01/2003

ADDITIONAL INFORMATION

Decrease of export turnover of Tallinn Pharmaceutical Plant

The first half-year 2003 export turnover of Tallinn Pharmaceutical Plant
decreased approximately 24% compared to year 2002 same period. Decrease of
export turnover is caused by reorganization of tablet production, change
of the tablets` sale and offset system (into year 2002 sales turnover had
been considered 100% of ointment, injection and tablet net sales, in year
2003 net sales has been indicated only the sales of ointments and
injections). Sales of tablets will be accounted separately and sales number
will make up a sales revenue, which will be equal to 23% royalty (from
tablets` net sales).


Planned profit and profitability in year 2003

By the budget the planned profit of Tallinn Pharmaceutical Plant for year
2003 is 7,9 mill EEK. The Board of Pharmaceutical Plant thinks that
fulfillment of budget is workable.
In company`s long term develpoment perspective in concern frames it is
important to increase company`s turnover and profitability (one of the
most imoprtant purposes is to raise profitability 15-18% at the end of
year 2005). To attain an object Tallinn Pharmaceutical Plant should
mobilize all the resources of company and concern.


Ibraim Muhtsi
Director
+372 6120201

Tradable Assets

Shares
Bonds
Funds

Market information

Statistics
Trading
Indexes
Auctions

Market Regulation

Rules and Regulations
Surveillance

Get Started

For Companies
For Investors
For Brokers/Members
For First North Advisers

News

Nasdaq News
Issuer News
Calendar

About Us

Nasdaq Baltic Market
Offices